Antimicrobial combinations against including benzoxadiazol-based flavodoxin inhibitors: characterization.

The antimicrobial resistance of () currently poses a threat to available treatment regimens. Developing antimicrobial drugs targeting new bacterial targets is crucial, and one such class of drugs includes -flavodoxin (-fld) inhibitors that target an essential metabolic pathway in . Our study demonstrated that combining these new drugs with conventional antibiotics used for infection treatment prevented the regrowth observed with drugs used alone. -fld inhibitors show promise as new drugs to be incorporated into the treatment of infection, potentially reducing the development of resistance and shortening the treatment duration.